View Document Preview and Link Document Date: 2010-05-21 21:24:13 Open Document File Size: 414,79 KB Share Result on Facebook
Company GlaxoSmithKline / Merck / US Vaccine Adverse Event / / Continent Europe / / Country United States / Australia / United Kingdom / / / Event FDA Phase / / IndustryTerm injection site / cervical cancer prevention technologies / / MedicalCondition paralysis / deep vein blood clots / allergic reaction / HIV / disease / cervical intraepithelial neoplasia grade / congenital abnormalities / Fainting / serious allergic reactions / HPV / Cervical cancer / HPV-related diseases / nausea / anaphylaxis / Fever / HPV infection / Syncope / genital warts / pain / injury / autoimmune disease / allergic reactions / Stop Cervical Cancer / infection / Guillain Barre Syndrome / illness / infections / spontaneous abortion / serious allergic reaction / adenocarcinoma / / MedicalTreatment immunization / oral contraceptives / vaccinations / vaccination / surgery / / Organization Global Advisory Committee on Vaccine Safety / World Health Organization / European Medicines Agency / Cervical Cancer Action Coalition / US Food and Drug Administration / Therapeutic Goods Administration / Global Coalition / Medicines and Healthcare Products Regulatory Agency / Centers for Disease Control and Prevention / / Product HPV Vaccine / virus-likeparticle vaccine / / Technology cervical cancer prevention technologies / pdf / / URL http / SocialTag 
Microsoft Word - CCA_HPV vaccine safety_Final.docx